BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 03, 2011
 |  BC Week In Review  |  Company News  |  Other News

Amphastar Pharmaceuticals generics news

Amphastar filed an amended complaint in the U.S. District Court for the District of Columbia seeking to require FDA to approve the company's ANDA for a generic enoxaparin. Amphastar claims FDA imposed testing standards unauthorized by law and developed by a competitor, as well as used the 2007-08 heparin crisis as a pretext for holding...

Read the full 253 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >